SBFM Earnings Sunshine Biopharma Inc.
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Latest filing
Annual results
EPS
Revenue
Net income
Quarterly results
EPS
Revenue
Net income
Reported EPS history
1–15 of 15
| Q2 2026 | 2026-06-30 | -1.15 | 2026-08-13 | 10-Q |
| Q1 2026 | 2026-03-31 | -2.50 | 2026-05-13 | 10-Q |
| Q4 2025 (derived) | 2025-12-31 | -4.16 | 2026-04-03 | 10-K |
| FY 2025 | 2025-12-31 | -14.40 | 2026-04-03 | 10-K |
| Q3 2025 | 2025-09-30 | -1.90 | 2025-11-13 | 10-Q |
| Q2 2025 | 2025-06-30 | -8.20 | 2025-08-12 | 10-Q |
| Q1 2025 | 2025-03-31 | -4.40 | 2025-05-15 | 10-Q |
| FY 2024 | 2024-12-31 | -73.20 | 2025-04-01 | 10-K |
| Q2 2024 | 2024-06-30 | -434.80 | — | — |
| Q1 2024 | 2024-03-31 | -20.00 | 2024-05-20 | 10-Q |
| FY 2023 | 2023-12-31 | -3513.60 | 2024-03-28 | 10-K |
| Q1 2023 | 2023-03-31 | -77.30 | 2023-05-10 | 10-Q |
| FY 2022 | 2022-12-31 | -1760.00 | 2023-04-04 | 10-K |
| Q1 2022 | 2022-03-31 | -230.00 | — | — |
| FY 2021 | 2021-12-31 | -4760.00 | — | — |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Q4 EPS marked "derived" is computed as the fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive across quarters, so it can differ by a cent or two from the issuer's own Q4. A period with no "Reported" date is known only from a later filing's prior-year comparative. Informational only — not financial advice.